These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193 [TBL] [Abstract][Full Text] [Related]
4. GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma. Ge L; Chen W; Cao W; Liu G; Zhang Q; Zhuang J; Zhang M; Yang J; Guo S; Zhao X; Guo H Cancer Biomark; 2018; 22(3):395-403. PubMed ID: 29865032 [TBL] [Abstract][Full Text] [Related]
5. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome. Cornejo KM; Dong F; Zhou AG; Wu CL; Young RH; Braaten K; Sadow PM; Nielsen GP; Oliva E Hum Pathol; 2015 Oct; 46(10):1411-7. PubMed ID: 26297250 [TBL] [Abstract][Full Text] [Related]
6. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Yu ZH; Zhang Q; Wang YD; Chen J; Jiang ZM; Shi M; Guo X; Qin J; Cui GH; Cai ZM; Gui YT; Lai YQ Asian Pac J Cancer Prev; 2013; 14(6):3729-34. PubMed ID: 23886173 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping. Alomari AK; Nettey OS; Singh D; Kluger H; Adeniran AJ Hum Pathol; 2015 Oct; 46(10):1418-26. PubMed ID: 26239624 [TBL] [Abstract][Full Text] [Related]
9. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis. Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054 [TBL] [Abstract][Full Text] [Related]
10. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145 [TBL] [Abstract][Full Text] [Related]
11. DNA ploidy pattern in papillary renal cell carcinoma. Correlation with clinicopathological parameters and survival. del Vecchio MT; Lazzi S; Bruni A; Mangiavacchi P; Cevenini G; Luzi P Pathol Res Pract; 1998; 194(5):325-33. PubMed ID: 9651945 [TBL] [Abstract][Full Text] [Related]
12. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients. Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911 [TBL] [Abstract][Full Text] [Related]
13. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Terakawa T; Miyake H; Kusuda Y; Fujisawa M Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464 [TBL] [Abstract][Full Text] [Related]
15. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience. Abolhasani M; Salarinejad S; Asgari M Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Stenman M; Laurell A; Lindskog M Med Oncol; 2014 Mar; 31(3):841. PubMed ID: 24477648 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481 [TBL] [Abstract][Full Text] [Related]
18. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD; PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212 [TBL] [Abstract][Full Text] [Related]
19. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888 [TBL] [Abstract][Full Text] [Related]